Close Menu

NEW YORK – Infectious and inflammatory disease diagnostics firm MeMed announced Wednesday that it has received €2.5 million ($2.8 million) in funding from the European Innovation Council to accelerate expansion of its MeMed BV test's applicability.

MeMed BV is an immune system-based protein signature test distinguishes between bacterial and viral infections and runs on the company's MeMed Key point-of-care platform. The Haifa, Israel-based company said in a statement it will use the money to widen MeMed BV's capability to include minimally invasive capillary blood samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.